0±0.5 to 1.21±0.5. In the 31 cases with no change in fibrosis, WFA-M2BP was also unchanged (0.98±0.50.92±0.4). In the 36 cases in which fibrosis improved, WFA-M2BP was significantly reduced (1.1±0.50.8±0.3; p<0.05). [Conclusion] Assessment of WFA-M2BP in NAFLD was considered useful in predicting progression of fibrosis and histological changes in NASH, as well as therapeutic effects. Specially, WFA-M2BP is useful predicting a Burn out NASH and future of HCC with NASH. Disclosures: The following people have nothing to disclose: Miwa Kawanaka, Ken Nishino, Jun Nakamura, Takahito Oka, Noriyo Urata, Daisuke Goto, Mitsuhiko Suehiro, Hirofumi Kawamoto, Gotaro Yamada Introduction:

X-396 datasheet Non-alcoholic steatohepatitis http://www.selleckchem.com/products/ly2606368.html (NASH) is a progressive form of non-alcoholic fatty liver disease (NAFLD) and an increasingly common cause of end-stage liver disease. While the pathogenesis of NASH is yet to be fully elucidated, recently 25-hydroxyvitamin D [25(OH)D] level has been purported to be independently

associated with the severity of liver histology in NASH. We therefore assessed any association between 25(OH)D level and liver histology in patients with biopsy-proven NASH. Methods: 35 patients with biopsy-proven NASH and recent 25(OH)D level within 4 months of liver biopsy were studied. Liver histology was assessed by a single pathologist using the NAFLD Activity Score (NAS) and Brunt fibrosis stage. Season of 25(OH)D level and use of vitamin D supplementation was noted. Recent anthropometric data, blood tests and liver

stiffness measurement (LSM) via transient elastography were obtained, with FIB-4 and NAFLD Fibrosis Score (NAS) calculated. Univariate and multivariate analysis was performed. Results: Mean age was 52.8 ± 9.6 years, with 18 (51.4%) male and 21 (60%) diabetic patients. Mean 25(OH)D level was 64.0 ± 28.0 nmol/L with 57.1% of 25(OH)D levels measured during Summer/Autumn months and 6 patients (17.1%) using vitamin D supplements. Mean liver biopsy length was 15.2 ± 3.5 mm with a median NAS of 5 and hepatocellular ballooning present in 97.1% (n=34) of patients. MCE Fibrosis stage prevalence was: F1 40.0% (n=14), F2 31.4% (n=11), F3 22.9% (n=8) and F4 5.7% (n=2). Mean 25(OH)D level was not associated with either NAS (OR 1.00, 95% CI 0.98-1.02; P=0.78), fibrosis stage (OR 1.00, 95% CI 0.98-1.02; P=0.89) or advanced (F3/4) fibrosis (OR 1.02, 95% CI 0.99-1.04; P=0.24), irrespective of whether patients on vitamin D supplementation were included in analysis. Predictors of liver histology on multivariate analysis are shown in Table 1. Conclusion: Mean 25(OH)D level appears to not be associated with either NAS or fibrosis stage in NASH. Further study on the impact of vitamin D supplementation on these parameters is warranted. Disclosures: Matthew T. Kitson – Consulting: MSD, Roche; Grant/Research Support: MSD; Speaking and Teaching: Janssen-Cilag Stuart K.